Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | See Remarks | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,683 |
Last balance in matching sequence
After 2026-10-02 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2026-10-01 · Exercise / conversion · Acquired 810 · Balance 6,493 F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 2 · 2026-10-01 · Sale · Disposed 810 · Balance 5,683 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 3 · 2026-10-02 · Exercise / conversion · Acquired 3,357 · Balance 9,040 F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 4 · 2026-10-02 · Exercise / conversion · Acquired 5,833 · Balance 14,873 F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 5 · 2026-10-02 · Sale · Disposed 4,446 · Balance 10,427 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction. F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $116.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 6 · 2026-10-02 · Sale · Disposed 4,744 · Balance 5,683 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction. F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.25 to $116.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.56 · Expires 2030-02-07 | Direct | 3,357 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 810 · Balance 3,357 F6: Fully exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.56 · Expires 2030-02-07 | Direct | 0 |
Reported balance
After 2026-10-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-02 · Exercise / conversion · Disposed 3,357 · Balance 0 F6: Fully exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.26 · Expires 2032-02-02 | Direct | 44,167 |
Reported balance
After 2026-10-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-02 · Exercise / conversion · Disposed 5,833 · Balance 44,167 F6: Fully exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $116.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.25 to $116.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6: Fully exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2025 Filed Jan 7, 2025 00:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,000 | $50.39 | $251,950.00 |
DisclosureSEC source: 0000950170-25-002446 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,759 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,000 | $11.35 | $56,750.00 |
DisclosureSEC source: 0000950170-25-002446 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 00:40 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 215 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-133439 · ownership.xml · nonDerivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,759 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 00:40 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 215 | $59.21 | $12,730.15 |
DisclosureSEC source: 0000950170-24-133439 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,544 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 2, 2024. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 00:40 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 165 | $57.68 | $9,517.20 |
DisclosureSEC source: 0000950170-24-133439 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,329 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain withholding obligations in connection with the issuance of share upon the vesting of restricted stock units. F2 · price: The closing price on November 29, 2024 was used to calculate the withholding obligation. F3 · balance_after: Includes 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 23:13 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,411 | $56.72 | $80,031.92 |
DisclosureSEC source: 0000950170-24-131170 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,494 F1 · balance_after: Includes 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 372 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-104205 · ownership.xml · nonDerivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,905 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 372 | $34.26 | $12,744.72 |
DisclosureSEC source: 0000950170-24-104205 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,533 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 3, 2024. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 129 | $35.30 | $4,553.70 |
DisclosureSEC source: 0000950170-24-104205 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,161 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on August 30, 2024 was used to calculate the withholding obligation. F3 · balance_after: Includes 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:16 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000950170-24-081631 · ownership.xml · derivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,167 Underlying: Common Stock · 5,000 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:16 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,000 | $32.49 | $162,452.00 |
DisclosureSEC source: 0000950170-24-081631 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,290 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $32.49 to $32.70 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F1 · balance_after: Includes 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:16 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,000 | $11.35 | $56,750.00 |
DisclosureSEC source: 0000950170-24-081631 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000950170-24-069608 · ownership.xml · derivative · entry 6 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,167 Underlying: Common Stock · 5,000 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-069608 · ownership.xml · nonDerivative · entry 5 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,290 F8 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F1 · balance_after: Includes 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,232 | $31.30 | $38,561.60 |
DisclosureSEC source: 0000950170-24-069608 · ownership.xml · nonDerivative · entry 4 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,058 F6 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 3, 2024. F7 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F1 · balance_after: Includes 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 488 | $30.17 | $14,722.96 |
DisclosureSEC source: 0000950170-24-069608 · ownership.xml · nonDerivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,826 F4 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F5 · price: The closing price on May 31, 2024 was used to calculate the withholding obligation. F1 · balance_after: Includes 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,000 | $30.18 | $150,916.00 |
DisclosureSEC source: 0000950170-24-069608 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,314 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $30.17 to $30.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F1 · balance_after: Includes 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,000 | $11.35 | $56,750.00 |
DisclosureSEC source: 0000950170-24-069608 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 09, 2024 Filed May 14, 2024 01:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 7,227 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000950170-24-059035 · ownership.xml · derivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,167 Underlying: Common Stock · 7,227 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 09, 2024 Filed May 14, 2024 01:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 7,227 | $26.00 | $187,902.00 |
DisclosureSEC source: 0000950170-24-059035 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,314 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F1 · balance_after: Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 09, 2024 Filed May 14, 2024 01:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 7,227 | $11.35 | $82,026.45 |
DisclosureSEC source: 0000950170-24-059035 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 02, 2024 Filed May 7, 2024 00:23 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 10,830 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000950170-24-053847 · ownership.xml · derivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,394 Underlying: Common Stock · 10,830 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 02, 2024 Filed May 7, 2024 00:23 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 10,830 | $26.00 | $281,580.00 |
DisclosureSEC source: 0000950170-24-053847 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,314 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F1 · balance_after: Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 02, 2024 Filed May 7, 2024 00:23 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,830 | $11.35 | $122,920.50 |
DisclosureSEC source: 0000950170-24-053847 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 22:16 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 5,443 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000950170-24-042725 · ownership.xml · derivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,224 Underlying: Common Stock · 5,443 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 22:16 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,443 | $26.00 | $141,523.99 |
DisclosureSEC source: 0000950170-24-042725 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,314 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $26.00 to $26.01 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F1 · balance_after: Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 22:16 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,443 | $11.35 | $61,778.05 |
DisclosureSEC source: 0000950170-24-042725 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 500 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000950170-24-041450 · ownership.xml · derivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,667 Underlying: Common Stock · 500 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 500 | $26.01 | $13,003.50 |
DisclosureSEC source: 0000950170-24-041450 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,314 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F1 · balance_after: Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 500 | $11.35 | $5,675.00 |
DisclosureSEC source: 0000950170-24-041450 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 02:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 507 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026782 · ownership.xml · nonDerivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,314 F5 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F2 · balance_after: Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 02:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 507 | $24.06 | $12,198.42 |
DisclosureSEC source: 0000950170-24-026782 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,807 F3 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2024. F4 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F2 · balance_after: Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 02:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 474 | $24.06 | $11,404.44 |
DisclosureSEC source: 0000950170-24-026782 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,300 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · balance_after: Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 1,000 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000950170-24-018325 · ownership.xml · derivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,167 Underlying: Common Stock · 1,000 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,000 | $26.00 | $26,000.00 |
DisclosureSEC source: 0000950170-24-018325 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,774 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:11 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 1,000 | $11.35 | $11,350.00 |
DisclosureSEC source: 0000950170-24-018325 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $23.01 | $0.00 |
DisclosureSEC source: 0000950170-24-014870 · ownership.xml · derivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-02-09 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 9, 2024 over a four-year period. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 23:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 2,432 | $26.00 | $63,232.00 |
DisclosureSEC source: 0000950170-23-068373 · ownership.xml · nonDerivative · entry 4 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,854 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 23:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 2,432 | $11.35 | $27,603.20 |
DisclosureSEC source: 0000950170-23-068373 · ownership.xml · nonDerivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000950170-23-068373 · ownership.xml · derivative · entry 7 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,167 Underlying: Common Stock · 5,000 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 460 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-068373 · ownership.xml · nonDerivative · entry 6 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,774 F5 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F1 · balance_after: Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 460 | $25.97 | $11,946.20 |
DisclosureSEC source: 0000950170-23-068373 · ownership.xml · nonDerivative · entry 5 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,314 F3 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on December 1, 2023. F4 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F1 · balance_after: Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 2,568 | $26.00 | $66,768.00 |
DisclosureSEC source: 0000950170-23-068373 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,854 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 2,568 | $11.35 | $29,146.80 |
DisclosureSEC source: 0000950170-23-068373 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 22:49 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 3,977 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000950170-23-058943 · ownership.xml · derivative · entry 6 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,167 Underlying: Common Stock · 3,977 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 22:49 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,977 | $28.11 | $111,794.27 |
DisclosureSEC source: 0000950170-23-058943 · ownership.xml · nonDerivative · entry 4 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,854 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $28.08 to $28.1244. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 22:49 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 3,977 | $11.35 | $45,138.95 |
DisclosureSEC source: 0000950170-23-058943 · ownership.xml · nonDerivative · entry 3 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:49 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 1,023 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000950170-23-058943 · ownership.xml · derivative · entry 5 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,144 Underlying: Common Stock · 1,023 shares Expires 2029-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:49 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,023 | $28.08 | $28,725.84 |
DisclosureSEC source: 0000950170-23-058943 · ownership.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,854 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:49 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 1,023 | $11.35 | $11,611.05 |
DisclosureSEC source: 0000950170-23-058943 · ownership.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.